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Objectives This study sought to evaluate the long-term mortality in patients with viral myocarditis, and to establish the
prognostic value of various clinical, functional, and cardiovascular magnetic resonance (CMR) parameters.
Background Long-termmortality of viral myocarditis, as well as potential risk factors for poor clinical outcome, are widely unknown.
Methods A total of 222 consecutive patients with biopsy-proven viral myocarditis and CMR were enrolled. A total of 203
patients were available for clinical follow-up, and 77 patients underwent additional follow-up CMR. The median
follow-up was 4.7 years. Primary endpoints were all-cause mortality and cardiac mortality.
Results We found a relevant long-term mortality in myocarditis patients (19.2% all cause, 15% cardiac, and 9.9% sud-
den cardiac death [SCD]). The presence of late gadolinium enhancement (LGE) yields a hazard ratio of 8.4 for
all-cause mortality and 12.8 for cardiac mortality, independent of clinical symptoms. This is superior to parame-
ters like left ventricular (LV) ejection fraction, LV end-diastolic volume, or New York Heart Association (NYHA)
functional class, yielding hazard ratios between 1.0 and 3.2 for all-cause mortality and between 1.0 and 2.2 for
cardiac mortality. No patient without LGE experienced SCD, even if the LV was enlarged and impaired. When
focusing on the subgroup undergoing follow-up CMR, we found an initial NYHA functional class I as the best
independent predictor for incomplete recovery (p  0.03).
Conclusions Among our population with a wide range of clinical symptoms, biopsy-proven viral myocarditis is associated with
a long-term mortality of up to 19.2% in 4.7 years. In addition, the presence of LGE is the best independent pre-
dictor of all-cause mortality and of cardiac mortality. Furthermore, initial presentation with heart failure may be
a good predictor of incomplete long-term recovery. (J Am Coll Cardiol 2012;59:1604–15) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2012.01.007Viral myocarditis is a common cardiac disease that is
identified in up to 9% of post-mortem examinations (1,2). It
appears to be a major cause of sudden, unexpected death (3),
and may progress to dilated cardiomyopathy (4,5).
Advanced diagnostic procedures such as cardiovascular
magnetic resonance (CMR) or immunohistologic and mo-
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2011, accepted January 2, 2012.lecular pathologic workup of endomyocardial biopsies pro-
vided new insights into this common, but not well charac-
terized, disease (6,7). However, the clinical management
remains difficult, and the long-term mortality of viral
myocarditis, as well as potential risk factors for poor clinical
outcome, are widely unknown.
Recent publications suggested several parameters that
may be associated with poor outcome (8–10), including
clinical symptoms, type of viruses, left ventricle (LV) size
and LV function, and late gadolinium enhancement (LGE),
which has been identified as a predictor of long-term
mortality in other nonischemic heart diseases (11,12).
Consequently, the primary objective was to evaluate the
long-term mortality in patients with viral myocarditis, as
well as to establish the long-term prognostic value of various
clinical, functional, and CMR parameters in this patient group.
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May 1, 2012:1604–15 Long-Term Follow-Up After MyocarditisSpecifically, we sought to demonstrate that the presence of
LGE predicts future cardiac death. In addition, we aimed at
describing predictors for incomplete recovery during long-term
follow-up.
Methods
Patient population. Two hundred twenty-two consecutive
atients presenting at our institution in Stuttgart for workup of
yocarditis (all comers; referrals [62.9%] and self-presenting
37.1%]) were enrolled in the long-term follow-up between
anuary 2002 and January 2008 if they fulfilled all of the following
riteria: 1) biopsy-proven viral myocarditis defined as presence of
yocardial inflammation and viral genome; 2) ruling out of
elevant coronary artery disease (stenosis 50%) by angiogra-
hy; and 3) CMR performed within 5 days of initial presen-
ation. Patients with valvular or congenital heart disease dem-
nstrated by CMR were not included. All patients gave
nformed consent. Some patients were also part of previous
eports (6,9).
MR protocol. Electrocardiography-gated CMR imaging
as performed in breath-hold using a 1.5T Magnetom
onata (Siemens Healthcare, Erlangen, Germany) in line
ith the Society of Cardiovascular Magnetic Resonance/
uropean Cardiovascular Magnetic Resonance recommen-
ations (13). Both cine and LGE short-axis CMR images
ere prescribed every 10 mm (slice thickness 6 mm) from
ase to apex. In-plane resolution was typically 1.2  1.8
m. Cine CMR was performed using a steady-state free
recession sequence. LGE images were acquired on average
to 10 min after contrast administration using segmented
nversion recovery gradient echo sequence (14) constantly
djusting inversion time (15). The contrast dose (gadodi-
mide or gadopentetate-dimeglumine) was 0.15 mmol/kg.
n addition, fat-saturated and T2-weighted images were
btained to allow differentiation between subepicardial
GE, epicardial fat, and pericardial effusion.
MR analysis. Cine and contrast images were evaluated by
wo experienced observers as described elsewhere (6,9). In
rief, endocardial and epicardial borders were outlined on the
hort-axis cine images. Volumes and ejection fraction (EF)
ere derived by summation of epicardial and endocardial
ontours. The LV mass was calculated by subtracting endo-
ardial from epicardial volume at end-diastole and multiplying
y 1.05 g/cm3 (16). Extent of LGE was assessed using the
iemens Healthcare Argus analysis software package and the
esults were expressed as percentage of myocardial mass.
ndomyocardial biopsy protocol. Endomyocardial biop-
ies were performed in all patients. At least five biopsies
ere preferentially taken from the ventricle demonstrating
GE. Patients demonstrating LGE exclusively in the LV
ateral wall underwent selective LV biopsies (30.9%), while
hose demonstrating LGE in the septum or having no LGE
t all underwent either biventricular (54.1%) or selective
ight ventricular biopsies (15%).istopathological analysis. En-
omyocardial biopsies were
tained with Masson’s trichrome
s well as Giemsa and examined
y light microscopy. For immu-
ohistology, tissue sections were
reated with an avidin-biotin-
mmunoperoxidase method (Vec-
astain Elite Kit, Vector, Burlin-
ame, California), applying the
ollowing monoclonal antibod-
es: CD3 (T-cells, Novocastra
aboratories, Newcastle, United
ingdom), CD68 (macro-
hages, DAKO, HAMBURG,
ERMANY), and human leuko-
yte antigen-DR (DAKO) as de-
cribed previously. The detection
f 14 infiltrating leukocytes/
m2 (CD3 T-lymphocytes
and/or CD68 macrophages) in
the presence of myocyte damage and/or fibrosis in addition
to enhanced human leukocyte antigen class II expression in
professional antigen-presenting immune cells and endothe-
lium was used for the diagnosis of myocarditis (6,9).
Detection of viral genomes. Deoxyribonucleic acid and
ribonucleic acid were extracted with the use of proteinase-K
digestion followed by extraction with phenol/chloroform.
Nested polymerase chain reaction/reverse transcriptase–
polymerase chain reaction was performed for the detection
of enteroviruses (including coxsackieviruses group A & B
and echoviruses), parvovirus B19 (PVB19), adenoviruses,
human cytomegalovirus, Epstein-Barr virus, and human
herpes virus type 6 (HHV6). As control for successful
extraction of deoxyribonucleic acid and ribonucleic acid,
oligonucleotide sequences were chosen from the
glyceraldehyde-3-phosphate-dehydrogenase gene. Specific-
ity of all viral amplification products was confirmed by
automatic deoxyribonucleic acid sequencing (6,9).
Clinical and CMR follow-up. Clinical follow-up was
performed using a standardized questionnaire at least 3
years after initial presentation. CMR follow-up using an
imaging protocol identical to that used initially was offered
to all surviving patients without contraindications to CMR.
In case of a suspected event, all necessary medical records
were obtained and reviewed by the authors acting as
endpoint committee.
Variables, endpoints, and definitions. All variables were
collected directly from patients, and/or medical records
except CMR parameters, which were evaluated as described
previously. Variables include general characteristics and
follow-up results. Most variables are self-explanatory; all
others are defined below.
There were three primary endpoints: 1) all-cause death,
defined as death from any cause, including aborted sudden
Abbreviations
and Acronyms
CMR  cardiovascular
magnetic resonance
EDV  end-diastolic volume
EF  ejection fraction
HHV  human herpes virus
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LGE  late gadolinium
enhancement
LV  left ventricle/left
ventricular
NYHA  New York Heart
Association
PVB19  parvovirus B19
SCD  sudden cardiac
deathcardiac death (SCD); 2) cardiac death, defined as death
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Long-Term Follow-Up After Myocarditis May 1, 2012:1604–15from all cardiac causes, including SCD, heart failure, and
aborted SCD; and 3) SCD, defined as unexpected arrest of
presumed cardiac origin within 1 h after onset of any
symptoms that could be interpreted as being cardiac in
origin. Aborted SCD was considered as resuscitation after
cardiac arrest defined as performance of the physical act of
cardioversion, appropriate implantable cardioverter-
defibrillator (ICD) shocks, or cardiopulmonary resuscita-
tion in a patient who remained alive 28 days later. For
appropriate ICD shocks, defibrillator discharges were
considered appropriate and included automatic defibril-
lation shocks triggered by ventricular tachycardia or
fibrillation and documented by stored intracardiac elec-
trocardiographic data.
Incomplete recovery was used as a secondary endpoint in the
group of patients with CMR follow-up. Incomplete recovery
was defined as EF 60% or end-diastolic volume (EDV)
180 ml, or clinical signs of heart failure (New York Heart
Association [NYHA] functional class I).
Statistical analysis. Absolute numbers and percentages
were computed to describe the patient population. Medians
(with interquartile range) or mean  SD were computed as
appropriate. Categorical values were compared by chi-
square test or Fisher exact test as appropriate. Kaplan-Meier
curves were calculated for visualizing the cumulative survival
of patients with and without LGE. A log-rank test was
performed to compare both survival curves. A multivariable
Cox proportional hazards model was used for analyzing
independent associations with all-cause and cardiac mortal-
ity. All p values 0.05 were considered significant. All p
alues are results of 2-tailed tests. All statistical analyses
ere performed using the SAS statistical package, version
.2 (SAS Institute, Cary, North Carolina).
esults
atient characteristics. Two hundred three of all 222
atients were available for clinical follow-up, yielding a
ollow-up rate of 91.5%. The remaining 19 patients were
ost due to no contact. The following paragraphs describe
he characteristics of the 203 patients who underwent
linical follow-up.
At inclusion, patients were 52 years old (interquartile
ange: 40 to 54). Chest pain was the primary reason to seek
edical attention (n  74), followed by new onset of heart
ailure (n  62), and various combinations of malaise and
alpitations (n  49) (Table 1). Most patients had an
bnormal electrocardiogram upon admission (n  188 of
203, 92.6%), with ST-segment abnormalities as the most
common finding (n 111 of 188, 59%), followed by bundle
branch block (n  20 of 188, 10.6%).
Endomyocardial biopsy revealed PVB19 as most frequent
virus (n  113), followed by HHV6 (n  49), and the
combination of PVB19 and HHV6 (n  35). Epstein-Barr
virus was also present, whereas other viruses were not found
(Table 1).All patients presenting with heart failure were treated
with state-of-the-art heart failure medication according to
guidelines. If indicated, an ICD was offered, which was
accepted by 23 patients. No patient in this cohort received
additional immunosuppressive, immunomodulatory, or an-
tiviral therapy.
CMR findings. The mean LVEF was 45% and the mean
Baseline Patient Characteristics(All Patients Wi h Clini al Follow-Up)Table 1 Baseline Pa ient Characteristics(All Patients With Clinical Follow-Up)
All patients with follow-up 203 (91.5)
Time to follow-up, days 1,685 (1,267–2,102)
Female 63 (31.0)
Age, yrs 52 (40–54)
BMI, kg/m2 26.3 (24.0–29.1)
BSA, m2 2.0 (1.8–2.1)
Primary clinical presentation
Symptoms of ACS 74 (36.5)
Subacute new-onset HF 62 (30.5)
Reoccurring episodes of overt HF 18 (8.9)
Combination of palpitations, fatigue,
dyspnea on exertion
49 (24.1)
Aborted SCD 0
Initial NYHA functional class
I 48 (23.6)
II 64 (31.5)
III 71 (35.0)
IV 20 (9.9)
Virus type by endomyocardial biopsy
PVB19 113 (55.7)
HHV6 49 (24.1)
PVB19/HHV6 35 (17.2)
EBV 2 (1.0)
PVB19/HHV6/EBV 1 (0.5)
PVB19/EBV 2 (1.0)
HHV6/EBV 1 (0.5)
Blood testing
Troponin positive 46 (22.7)
BNP, pg/ml 190 (39–652)
NT-proBNP, pg/ml 1,938 (220–8822)
CMR imaging parameter
LVEF, % 45 (31–60)
EF indexed, %/m2 23.7 (15.9–31.2)
LVEDV, ml 167 (129–210)
LVESV, ml 90 (47–144)
LGE present 108 (53.2)
LGE mass, g 5.3 (3.2–18.6)
LGE, % of LV mass 4.2 (2.3–9.3)
Event
All-cause death 39 (19.2)
Cardiac death 29 (15.0)
SCD 18 (9.9)
Values are n (%) or median (interquartile range).
ACS  acute coronary syndrome; BMI  body mass index; BNP  B-type natriuretic peptide;
BSA  body surface area; CMR  cardiovascular magnetic resonance; EBV  Epstein-Barr virus;
HF heart failure; HHV6 human herpes virus type 6; LGE late gadolinium enhancement; LV
left ventricle/left ventricular; LVEDV left ventricular end-diastolic volume; LVEF left ventricular
ejection fraction; LVESV left ventricular end-systolic volume; NT-proBNP N-terminal pro–B-type
natriuretic peptide; NYHA New York Heart Association; PVB19 parvovirus B19; SCD sudden
ardiac death.LVEDV was 167 ml (Table 1). LGE was present in 108 of
(Table
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May 1, 2012:1604–15 Long-Term Follow-Up After Myocarditis203 patients. LGE was usually located in the subepicardial
or intramural areas of the LV.
Using the presence of LGE as only diagnostic criterion, the
sensitivity of LGE to detect myocarditis was 53.2%. However,
when also taking morphological and functional information
into account, we found that 170 of 203 patients had an
abnormal CMR (LVEF 60% and/or LVEDV 180 ml
and/or presence of LGE). Thus, the overall diagnostic perfor-
mance of CMR to detect myocarditis was 83.7% using mor-
phology, function, and LGE according to 2008 Society of
Cardiovascular Magnetic Resonance/European Cardiovascular
Magnetic Resonance recommendations (13).
Dividing our patient population in groups with and without
LGE reveals that patients with LGE had larger ventricles,
poorer LVEF, and were more likely to have elevated levels of
B-type natriuretic peptide (Table 2). However, we did not find
Characteristics of Patients With and Without LGTable 2 Characteristics of Patients With an
LGE Present
(n  108)
Age, yrs 55.0 (40.5–67.5)
Female 26 (24.1)
BMI, kg/m2 26.8 (24.5–29.4)
BSA, m2 2.0 (1.8–2.2)
Primary clinical presentation
Symptoms of ACS 37 (34.3)
Subacute new-onset heart failure 37 (34.3)
Reoccurring episodes of overt HF 11 (10.2)
Combination of palpitations,
fatigue, dyspnea on exertion
23 (21.3)
Aborted SCD 0 (0)
Initial NYHA functional class
I 25 (23.1)
II 32 (29.6)
III 40 (37)
IV 11 (10.2)
Virus type by endomyocardial biopsy
PVB19 61 (56.5)
HHV6 23 (21.3)
PVB19/HHV 6 20 (18.5)
EBV 1 (0.9)
PVB19/HHV6/EBV 1 (0.9)
PVB 19/EBV 2 (1.9)
HHV6/EBV 0 (0)
Blood testing
Troponin positive 30 (27.8)
BNP, pg/ml 336 (82–983)
NT-proBNP, pg/ml 2,359 (547–18,09
CMR imaging parameter
LVEF, % 37.5 (24.5–57.0)
EF indexed, %/m2 19.9 (12.7–28.4)
LV-EDV, ml 187.5 (140–263)
LV-ESV, ml 119.5 (57.5–179.0
LGE mass, g 5.3 (3.2–18.6)
LGE, % of LV mass 4.2 (2.3–9.3)
Values are median (25th–75th percentile) or n (%).
CI  confidence interval; OR  odds ratio; other abbreviations as insignificant differences in clinical symptoms or type of virusesbetween the 2 groups with and without LGE (Table 2).
Typical CMR results are displayed in Figure 1.
Follow-up results. During follow-up 28 of 203 patients
died, and 11 patients survived SCD due to adequate ICD
discharge. Those 11 patients were also counted as events as
described previously (Table 1). The majority of events (n 29)
occurred for cardiac reasons, and the remaining 10 events were
related to cancer, fatal infections, or accidents. Note that no
patient with normal CMR at initial presentation (n  33) died.
Seventy-seven of the surviving patients without ICD
n 141) agreed to undergo follow-up CMR in addition to
clinical follow-up (54.6%). The mean time between initial
and follow-up CMR was 4.7 years. During this time 24 of
the 77 patients recovered fully (LVEF60% and LVEDV180
ml and no clinical signs of heart failure).
Predictors of events. For evaluation of predictors for
hout LGE
No LGE
(n  95) p Value OR (95% CI)
50.0 (38.0–59.0) 0.08
37 (38.9) 0.05 0.50 (0.27–0.91)
25.8 (23.5–28.4) 0.16
1.9 (1.8–2.1) 0.05
37 (38.9) 0.49 0.82 (0.46–1.45)
25 (26.3) 0.22 1.46 (0.80–2.67)
7 (7.4) 0.48 1.43 (0.53–3.84)
26 (27.4) 0.31 0.72 (0.38–1.37)
0 (0) 1.00
23 (24.2) 0.86 0.94 (0.49–1.80)
32 (33.7) 0.53 0.83 (0.46–1.50)
31 (32.6) 0.51 1.21 (0.68–2.17)
9 (9.5) 0.87 1.08 (0.43–2.74)
52 (54.7) 0.80 1.07 (0.62–1.87)
26 (27.4) 0.31 0.72 (0.38–1.37)
15 (15.8) 0.61 1.21 (0.58–2.53)
1 (1.1) 0.93 0.88 (0.05–14.24)
0 (0) 0.35
0 (0) 0.18
1 (1.1) 0.29
16 (16.8) 0.06 1.90 (0.96–3.76)
67 (27–457) 0.001
1,938 (38–4,391) 0.55
53.0 (39.0–64.0) 0.0001
26.8 (19.6–33.8) 0.0001
155.0 (120–193) 0.001
73.0 (43.0–113.0) 0.0001
—
—
1.Ed Wit
2)
)events we looked at: 1) all patients who experienced any
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experienced cardiac death (cardiac mortality); and 3) the
subgroup of patients experiencing SCD. Univariate analysis
(all-cause mortality, cardiac mortality, SCD) is displayed in
Table 3, 4, and 5. There is no significant correlation
between events and clinical presentation (except reoccurring
episodes of overt heart failure), type of virus, or positive
troponin at initial presentation. However, there is a trend to
poorer outcome in combined PVB19/HHV6 infection.
Besides age, which is obviously related to mortality and
morbidity, functional parameters such as LVEF, LVEDV,
and the presence of LGE reached statistical significance. In
fact, the presence of LGE yields an odds ratio for death of
24.2 in the all-cause mortality group and 36.7 in the cardiac
mortality group. The odds ratio for SCD could not be
calculated because no patient without LGE experienced
SCD. Typical examples are displayed in Figure 2.
Kaplan-Meier survival curves for all-cause mortality,
cardiac mortality, and SCD comparing patients with LGE
Figure 1 Typical Cardiac Magnetic Resonance Results
Cardiovascular magnetic resonance of a 25-year-old male patient presenting for w
ventricle (LV) with severely impaired left ventricular ejection fraction (LVEF). Late g
24% of LV mass. Endomyocardial biopsy revealed human herpes virus type 6 myo
findings in a 52-year-old female presenting for workup of chest pain. LVEF and LV
virus B19 myocarditis. LVEDV  left ventricular end-diastolic volume.with patients without LGE are displayed in Figures 3A to 3C.Note that only 1 patient without LGE experienced cardiac
death during follow-up (Fig. 3B) and that no patient
without LGE experienced SCD (Fig. 3C).
Multivariable Cox proportional hazards regression anal-
ysis including the initial presence of LGE, the initial LVEF,
the initial LVEDV, and the initial NYHA functional class
also revealed LGE as the best independent predictor of
all-cause mortality (hazard ratio [HR]: 8.4, p  0.004). In
this model neither initial LVEDV (HR per milliliter in-
crease in LVEDV: 1.003, p  0.08), nor initial NYHA
functional class (HR: 3.2, p  0.11), nor initial LVEF (HR
per percent increase in LVEF: 0.98, p  0.13) reached
significance. Looking at patients experiencing cardiac death
only, LGE was also the best independent predictor of
cardiac death (HR: 12.8, p  0.01). Also in this model
neither initial LVEDV (HR per milliliter increase in
LVEDV: 1.004, p  0.09), nor initial LVEF (HR per
percent increase in LVEF: 0.98, p  0.16), nor initial
NYHA functional class (HR: 2.2, p  0.30) reached
of new heart failure (top row, Patient #169). Cine images show an enlarged left
um enhancement (LGE) is present in many areas (white arrows) adding up to
s. The bottom row (Patient #130) displays cardiovascular magnetic resonance
normal (cine) and no LGE can be found. This patient was diagnosed with parvo-orkup
adolini
carditi
size issignificance. Those results do not change if the variable
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regression models (HR: 0.77, p  0.45). For SCD the
analysis could not be performed because no patient without
LGE experienced SCD.
When focusing on the 77 patients that underwent CMR
follow-up, univariate analysis revealed an initial NYHA
functional class I as the best predictor of incomplete
recovery, followed by initial LVEF (Table 6). This finding
was also confirmed by multivariable regression revealing
initial NYHA functional class I as the best independent
predictor of incomplete recovery (p  0.03). In this
model neither initial LVEF (p  0.16), nor initial LVEDV
p  0.61), nor LGE (p  0.70) reached significance.
Univariate Analysis: All-Cause MortalityTable 3 Univariate Analysis: All-Cause Mort
No Event
(n  164)
Age, yrs 50.0 (38.5–63.0)
Female 51 (31.1)
BMI, kg/m2 26.3 (24.1–29.1)
BSA, m2 2.0 (1.8–2.1)
Primary clinical presentation
Symptoms of ACS 62 (37.8)
Subacute new-onset HF 49 (29.9)
Reoccurring episodes of
overt HF
10 (6.1)
Combination of palpitations,
fatigue, dyspnea on
exertion
43 (26.2)
Aborted SCD 0 (0)
Initial NYHA functional class
I 46 (28.0)
II 52 (31.7)
III 51 (31.1)
IV 15 (9.1)
Virus type by endomyocardial
biopsy
PVB19 95 (57.9)
HHV6 41 (25.0)
PVB19/HHV6 26 (15.9)
EBV 1 (0.6)
PVB19/HHV6/EBV 0 (0)
PVB19/EBV 0 (0)
HHV6/EBV 1 (0.6)
Blood testing
Troponin positive 34 (20.7)
BNP, pg/ml 152 (35–511)
NT-proBNP, pg/ml 1,132 (69–3,055)
CMR imaging parameter
LVEF, % 52.5 (34.0–63.5)
EF indexed, %/m2 26.0 (17.8–32.9)
LVEDV, ml 160.0 (123.5–198.0)
LVESV, ml 77.5 (44.0–125.5)
LGE present 71 (43.3)
LGE mass, g 4.5 (2.2–7.8)
LGE, % of LV mass 3.2 (1.9–5.5)
Values are median (25th–75th percentile) or n (%).
Abbreviations as in Tables 1 and 2.igure 4 compares typical initial to follow-up CMR results. miscussion
his study is unique in that we could demonstrate that the
resence of LGE is the best independent predictor of death
n patients with viral myocarditis. In comparison with
revious studies (8,10,17,18), we only included patients
ith biopsy-proven viral myocarditis, who all underwent
MR imaging within 5 days after initial presentation. Our
ata indicate that there is a relevant long-term mortality in
yocarditis patients (Table 1). In addition the presence of
GE may be useful for noninvasive risk stratification of
yocarditis patients, yielding a Cox proportional hazards
R of 8.4 for all-cause mortality and 12.8 for cardiac
ll-Cause Death
(n  39) p Value OR (95% CI)
.0 (44.0–69.0) 0.05
2 (30.8) 0.97 0.98 (0.46–2.10)
.0 (23.6–28.7) 0.86
.0 (1.8–2.2) 0.26
2 (30.8) 0.41 0.73 (0.35–1.55)
3 (33.3) 0.67 1.17 (0.56–2.47)
8 (20.5) 0.01 3.97 (1.45–10.87)
6 (15.4) 0.16 0.51 (0.20–1.31)
0 (0)
2 (5.1) 0.01 0.14 (0.03–0.60)
2 (30.8) 0.91 0.96 (0.45–2.04)
0 (51.3) 0.05 2.33 (1.15–4.74)
5 (12.8) 0.49 1.46 (0.50–4–30)
8 (48.2) 0.18 0.62 (0.31–1.26)
8 (20.5) 0.56 0.77 (0.33–1.82)
9 (23.1) 0.28 1.59 (0.68–3.74)
1 (2.6) 0.27 4.29 (0.26–70.13)
1 (2.6) 0.05
2 (5.1) 0.01
0 (0) 0.62
2 (30.8) 0.18 1.70 (0.78–3.70)
4 (140–1,432) 0.01
7 (1,444–18,092) 0.12
.0 (20.0–42.0) 0.0001
.3 (9.6–21.0) 0.0001
.0 (181.0–312.0) 0.0001
.0 (119.0–214.0) 0.0001
7 (94.8) 0.0001 24.23 (5.65–103.9)
.9 (5.2–30.9) 0.0001
.7 (4.6–20.4) 0.0001ality
A
61
1
26
2
1
1
1
2
1
1
67
3,69
34
16
207
149
3
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LVEDV, or NYHA functional class, yielding HRs between
1.0 and 3.2 for all-cause mortality and between 1.0 and
2.2 for cardiac mortality. Importantly, in our population
no patient without LGE experienced SCD, even if the
LV was enlarged and the LVEF was severely impaired
(LVEDV 180 ml and LVEF 35% and no LGE; n 
14) (Fig. 3C).
Patient characteristics. Most patients presented for workup
of chest pain or heart failure, which is in line with previous
results (6,9,19). Also types of viruses found are similar to our
(6,9,19) and other previous reports (10,20). In addition to chest
pain and heart failure patients presented with a broad variety of
Univariate Analysis: Cardiac MortalityTable 4 Univariate Analysis: Cardiac Mortal
No Event
(n  164)
Age, yrs 50.0 (38.5–63.0)
Female 51 (31.1)
BMI, kg/m2 26.3 (24.1–29.1)
BSA, m2 2.0 (1.8–2.1)
Primary clinical presentation
Symptoms of ACS 62 (37.8)
Subacute new-onset HF 49 (29.9)
Reoccurring episodes of
overt HF
10 (6.1)
Combination of palpitations,
fatigue, dyspnea on
exertion
43 (26.2)
Aborted SCD 0 (0)
Initial NYHA functional class
I 46 (28.0)
II 52 (31.7)
III 51 (31.1)
IV 15 (9.1)
Virus type by endomyocardial
biopsy
PVB19 95 (57.9)
HHV6 41 (25.0)
PVB19/HHV6 26 (15.9)
EBV 1 (0.6)
PVB19/HHV6/EBV 0 (0)
PVB19/EBV 0 (0)
HHV6/EBV 1 (0.6)
Blood testing
Troponin positive 34 (20.7)
BNP, pg/ml 152 (35–511)
NT-proBNP, pg/ml 1,132 (69–3,055)
CMR imaging parameter
LVEF, % 52.5 (34.0–63.5)
EF indexed, %/m2 26.0 (17.8–32.9)
LVEDV, ml 160 (123.5–198.0)
LVESV, ml 77.5 (44.0–125.5)
LGE present 71 (43.3)
LGE mass, g 4.5 (2.2–7.8)
LGE, % of LV mass 3.2 (1.9–5.5)
Values are median (25th–75th percentile) or n (%).
Abbreviations as in Tables 1 and 2.symptoms, ranging from mild to severe. Nevertheless, incomparison with previous studies (6,9) the current patients are
less symptomatic on average. This is also reflected by the fact
that in the current population just 22.7% of patients had
elevated troponin at presentation.
CMR findings. We found a broad range of normal or
dilated ventricles with either normal or impaired function.
LGE was present in 108 of 203 patients, and was usually
located in the subepicardial or intramural areas of the LV,
which is in line with previous findings (6,9,21).
The sensitivity for LGE to detect myocarditis was 53.2%
in the current study, which is lower than that in our previous
reports (6,9), but well in line with the mean sensitivity of
LGE of 59% described in a recent meta-analysis (22). The
Cardiac Death
(n  29) p Value OR (95% CI)
.0 (47.0–67.0) 0.05
6 (20.7) 0.26 0.58 (0.22–1.51)
.9 (24.1–29.6) 0.59
.1 (1.9–2.2) 0.05
1 (37.9) 0.99 1.01 (0.45–2.27)
9 (31) 0.90 1.06 (0.45–2.48)
5 (17.2) 0.05 3.21 (1.01–10.20)
4 (13.8) 0.15 0.45 (0.15–1.37)
0 (0)
2 (6.9) 0.05 0.19 (0.04–0.83)
9 (31.0) 0.94 0.97 (0.41–2.27)
3 (44.8) 0.15 1.80 (0.81–4.02)
5 (17.2) 0.19 2.07 (0.69–6.22)
4 (48.3) 0.33 0.68 (0.31–1.50)
5 (17.2) 0.37 0.63 (0.22–1.74)
7 (24.1) 0.27 1.69 (0.65–4.36)
1 (3.4) 0.16 5.82 (0.35–95.8)
1 (3.4) 0.05
1 (3.4) 0.05
0 (0.0) 0.67
0 (34.5) 0.10 2.01 (0.86–4–73)
4 (107–1,432) 0.01
3 (1,146–15,563) 0.18
.0 (19.0–42.0) 0.0001
.5 (8.4–21.0) 0.0001
.0 (190.0–312.0) 0.0001
.0 (125.0–224.0) 0.0001
8 (96.6) 0.0001 36.68 (4.87–276.1)
.7 (5.2–35.4) 0.0001
.0 (5.1–22.0) 0.0001ity
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severity. The overall sensitivity of CMR to detect myocar-
ditis using morphology, function, and LGE as described
previously was 83.7%.
Furthermore, our data demonstrate that patients with
scar indicated by LGE have larger ventricles and poorer
LVEF compared with those without scar (Table 2). This
finding is illustrated in Figure 1, and nicely matches the
results from Assomull et al. (11), who reported the same
relationship in dilated cardiomyopathy. As scarring may
lead to LV dilatation and impaired LVEF, this finding
conceptually makes sense.
Follow-up results and predictors of events. In our popu-
Univariate Analysis: SCDTable 5 Univariate Analysis: SCD
No Event
(n  164)
Age, yrs 50.0 (38.5–63.0)
Female 51 (31.1)
BMI, kg/m2 26.3 (24.1–29.1)
BSA, m2 2.0 (1.8–2.1)
Primary clinical presentation
Symptoms of ACS 62 (37.8)
Subacute new-onset HF 49 (29.9)
Reoccurring episodes of
overt HF
10 (6.1)
Combination of palpitations,
fatigue, dyspnea on
exertion
43 (26.2)
Aborted SCD 0 (0)
Initial NYHA functional class
I 46 (28.0)
II 52 (31.7)
III 51 (31.1)
IV 15 (9.1)
Virus type by endomyocardial
biopsy
PVB19 95 (57.9)
HHV6 41 (25.0)
PVB19/HHV6 26 (15.9)
EBV 1 (0.6)
PVB19/HHV6/EBV 0 (0)
PVB19/EBV 0 (0)
HHV6/EBV 1 (0.6)
Blood testing
Troponin positive 34 (20.7)
BNP, pg/ml 152 (35–511)
NT-proBNP, pg/ml 1,132 (69–3,055)
CMR imaging parameter
LVEF, % 52.5 (34–63.5)
EF indexed, %/m2 26.0 (17.8–32.9)
LVEDV, ml 160.0 (123.5–198.0)
LVESV, ml 77.5 (44.0–125.5)
LGE present 71 (43.3)
LGE mass, g 4.5 (2.2–7.8)
LGE, % of LV mass 3.2 (1.9–5.5)
Values are median (25th–75th percentile) or n (%).
Abbreviations as in Tables 1 and 2.lation with symptoms ranging from mild to severe all-causemortality was 19.2%, cardiac mortality was 15%, and SCD
occurred in 9.9% of patients during follow-up. Thus, our event
rate is lower than in the Mason et al. myocarditis trial (23),
most likely due to different inclusion criteria and disease
severity, but is almost as high as in the nonischemic cardio-
myopathy group of the SCD-HeFT (Sudden Cardiac Death
in Heart Failure) trial (24), although LV function was much
better in our patients, underscoring the importance of risk
stratification and optimal clinical management in myocarditis.
In the group of 39 patients experiencing death during
follow-up, most individuals died from cardiac events (n 29),
emphasizing that cardiac events are the main cause of mortality
among various symptomatic myocarditis patients. In the clin-
SCD
(n  18) p Value OR (95% CI)
0.5 (47.0–65.0) 0.11
3 (16.7) 0.20 0.44 (0.12–1.60)
7.3 (25.4–33.1) 0.25
2.1 (1.9–2.2) 0.05
6 (33.3) 0.71 0.82 (0.29–2.30)
6 (33.3) 0.76 1.17 (0.42–3.31)
3 (16.7) 0.10 3.08 (0.76–12.43)
3 (16.7) 0.38 0.56 (0.16–2.04)
0 (0)
1 (5.6) 0.05 0.15 (0.02–1.17)
3 (16.7) 0.19 0.43 (0.12–1.55)
11 (61.1) 0.05 3.48 (1.28–9.50)
3 (16.7) 0.31 1.99 (0.52–7.65)
9 (50.0) 0.52 0.73 (0.27–1.92)
3 (16.7) 0.43 0.60 (0.17–2.18)
4 (22.2) 0.49 1.52 (0.46–4.97)
1 (5.6) 0.06 9.59 (0.57–160.3)
0 (0)
1 (5.6) 0.01
0 (0) 0.74
6 (33.3) 0.22 1.91 (0.67–5.46)
90 (165–1,432) 0.01
42 (1,146–3,003) 0.49
0.0 (19.0–42.0) 0.0001
3.7 (8.4–19.7) 0.0001
2.0 (196.0–331.0) 0.001
6.5 (119.0–266.0) 0.001
18 (100.0) 0.0001
7.7 (3.8–24.9) 0.05
6.2 (2.8–19.9) 0.056
2
8
1,7
3
1
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Long-Term Follow-Up After Myocarditis May 1, 2012:1604–15functional parameters remains difficult despite the value of
LVEF, LVEDV, and NYHA functional class (8,10,17). For
example, in the current study 11 patients in NYHA functional
classes I and II experienced cardiac death, 4 of them SCD
(Table 5). In addition, several patients died despite only mildly
impaired LV function (n  5, LVEF 45%) or a normal-
sized LV (n  13, LVEDV 180 ml). Other factors, such as
he type of virus detected in the myocardium, suggested to be
f prognostic value in previous studies (8,9) could not yet be
onfirmed, despite a trend toward a poorer outcome in patients
ith combined PVB19/HHV6 myocarditis, which is in line
ith previous findings (9,20).
Our findings fit to the fact that LGE has also been shown
o be a good predictor of adverse events in other nonisch-
mic heart diseases, such as dilated (11) or hypertrophic
ardiomyopathy (12). These results may help to explain why
o patient without LGE experienced SCD (0 of 18)
Table 2), and only 1 patient without LGE experienced
ardiac death (1 of 29) (Table 2), even when the LVEF was
everely impaired and/or the LV was severely dilated. This
oncept is highlighted by Figure 2.
Even with our encouraging data, however, it is important
o keep in mind that there is not a 1-to-1 relationship
etween the presence of LGE and cardiac death. Thus, to
urther improve possible CMR risk stratification, we also
Figure 2 LV Function, Presence of LGE, and Sudden Cardiac De
The top row demonstrates cardiovascular magnetic resonance findings of a 73-ye
mildly impaired LV with mostly septal LGE (27% of LV mass, white arrows). He cli
years after initial presentation, despite only mildly impaired LVEF. The middle row
combined parvovirus B19/human herpes virus type 6 myocarditis (Patient #121).
tions (white arrows, 21% of LV mass). This patient never completely recovered an
Cardiovascular magnetic resonance results of a 54-year-old male diagnosed with h
The LV is also dilated and LVEF is severely impaired, but no LGE is present. Thishought about a possible incremental value of additional tMR-related parameters, such as the pattern of LGE (9),
car volume and surface area (12), or decrease of LGE over
ime (6). However, we were not able to discriminate their
ndividual predictive potential due to the limited number of
ases and events available in the present study. This topic
hall be revisited when the data of the European Cardio-
ascular Magnetic Resonance Registry or the Magnetic
esonance in Myocarditis Registry becomes available.
When focusing on the subgroup of patients who also
nderwent follow-up CMR (n  77), analysis revealed an
nitial NYHA functional class I as the best independent
redictor for incomplete recovery (p 0.03), matching results
rom other studies (8,10,17), whereas surprisingly LGE does
ot seem to play a relevant role in this setting. This concept is
ighlighted by Figure 4. However, one needs to keep in mind
hat this subgroup of patients undergoing follow-up CMR
bviously lacks all patients that died during follow-up (n 39)
nd all patients who received an ICD (n  23), causing a
election bias possibly affecting reliability and resulting in an
nderestimation of the role of LGE.
linical implications. Although our data demonstrate an
ssociation between LGE and death in myocarditis patients,
rospectively designed international trials are required to
efinitively establish LGE as causally related to death risk,
specially because myocarditis populations in other coun-
ale with parvovirus B19 myocarditis (Patient #136). This patient has a dilated,
recovered from myocarditis, but experienced sudden cardiac death about 3.5
cardiovascular magnetic resonance images of a 65-year-old male patient with
is enlarged and LVEF is severely impaired, and LGE is present at multiple loca-
rienced cardiac death from heart failure about 2 years after initial presentation.
herpes virus type 6 myocarditis (Patient #88) can be viewed in the bottom row.
was still alive at follow-up. Abbreviations as in Figure 1.ath
ar-old m
nically
shows
The LV
d expe
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patientries may show lower incidences of PVB19. However, with
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May 1, 2012:1604–15 Long-Term Follow-Up After Myocarditisregard to our data and the results from other groups some
speculations could be made that may influence clinical man-
agement. 1) Myocarditis patients with normal CMR (LVEF
60% and LVEDV 180 ml and no LGE) seem to have a
ood prognosis. Thus, patients with clinically suspected myo-
arditis and normal CMR are also likely to have a good
rognosis, which may give afflicted patients and worrying
hysicians some peace of mind. 2) Myocarditis patients with-
Figure 3 Kaplan-Meier Survival Curves for All-Cause, Cardiac, a
Kaplan-Meier survival curves with regard to all-cause mortality (A), cardiac mortali
bottom of the figure. Note that in the group without any scar not a single patient e
resonance; other abbreviation as in Figure 1.ut LGE did not experience SCD in our study, even if the LV fas dilated and the LVEF severely impaired. Consequently, if
GE and not LV function or size is closer to the substrate for
CD, we may speculate about treating all myocarditis patients
emonstrating LGE with beta-blockers, independent of LV
unction and size, to prevent potentially lethal arrhythmias.
his speculation satisfactorily fits to the results of Kindermann
t al. (10), describing the lack of beta-blocker therapy as a
redictor for poor clinical outcome. 3) We found initial heart
udden Cardiac Death
and sudden cardiac death (C). The number of patients at risk is shown at the
nced sudden cardiac death during follow-up. CMR  cardiovascular magneticnd S
ty (B),
xperieailure (NYHA functional class I) as the best predictor for
as LVE
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Long-Term Follow-Up After Myocarditis May 1, 2012:1604–15incomplete recovery. Despite the limitations discussed
previously, one should carefully optimize heart failure
therapy in all myocarditis patients presenting with even
the mildest signs of heart failure to improve the chance of
complete recovery.
Conclusions
Among our population with a wide range of clinical symp-
toms, biopsy-proven viral myocarditis is associated with a
long-term mortality of up to 19.2% in 4.7 years. In addition,
the presence of scar indicated by LGE is the best indepen-
Univariate Analysis: Predictors for Incomplete RTable 6 Univariate Analysis: Predictors for I
Full Recovery*
(n  24)
Age, yrs 40.0 (33.0–50.5.0)
Female 6 (25)
BMI, kg/m2 26.0 (24.0–28.4)
BSA, m2 2.1 (2.0–2.1)
Primary clinical presentation
Symptoms of ACS 10 (41.7)
Subacute new-onset HF 3 (12.5)
Reoccurring episodes of
overt HF
2 (8.3)
Combination of palpitations,
fatigue, dyspnea on
exertion
9 (37.5)
Aborted SCD 0 (0)
Initial NYHA functional class
I 15 (62.5)
II 7 (29.2)
III 1 (4.2)
IV 1 (4.2)
Virus type by endomyocardial
biopsy
PVB19 12 (50)
HHV6 6 (25)
PVB19/HHV6 6 (25)
EBV 0 (0)
PVB19/HHV6/EBV 0 (0)
PVB19/EBV 0 (0)
HHV6/EBV 0 (0)
Blood testing
Troponin positive 6 (25.0)
BNP, pg/ml 62 (23–139)
NT-proBNP, pg/ml 86.5 (37–1,037)
CMR imaging parameter
(baseline)
LVEF, % 62.5 (52–68.5)
EF indexed, %/m2 31.6 (24.3–34.0)
LVEDV, ml 147.5 (125.5–169.0)
LVESV, ml 49.0 (42.5–84.5)
LGE present 10 (41.7)
LGE mass, g 4.3 (1.2–8.8)
LGE, % of LV mass 3.2 (1.4–7.4)
Values are median (25th–75th percentile) or n (%). Only patients with follow
180 ml and no signs of heart failure. †Incomplete recovery is defined
Abbreviations as in Tables 1 and 2.dent predictor of all-cause mortality and cardiac mortality.Furthermore, initial presentation with heart failure (NYHA
functional class I) may be a good predictor of incomplete
long-term recovery. These data support the necessity for
future large longitudinal follow-up studies to definitely
establish LGE as an independent predictor of cardiac death
in viral myocarditis, as well as to evaluate the incremental
prognostic value of additional parameters.
Reprint requests and correspondence: Dr. Heiko Mahrholdt,
Robert-Bosch-Medical Center, Auerbachstrasse 110, 70376 Stutt-
gart, Germany. E-mail: Heiko.Mahrholdt@rbk.de.
eryplete Recovery
omplete Recovery†
(n  53) p Value OR (95% CI)
52.0 (43.0–64.0) 0.01
20 (37.7) 0.27 0.55 (0.19–1.62)
26.8 (24.0–30.6) 0.57
1.9 (1.8–2.1) 0.08
23 (43.4) 0.89 0.93 (0.35–2.47)
16 (30.2) 0.10 0.33 (0.09–1.27)
2 (3.8) 0.40 2.32 (0.31–17.52)
12 (22.6) 0.18 2.05 (0.72–5.84)
0 (0)
15 (28.3) 0.58 4.22 (1.52–11.71)
13 (24.5) 0.67 1.27 (0.43–3.73)
21 (39.6) 0.01 0.07 (0.01–0.53)
4 (7.5) 0.01 0.53 (0.06–5.04)
29 (54.7) 0.70 0.83 (0.32–2.17)
16 (30.2) 0.64 0.77 (0.26–2.30)
7 (13.2) 0.20 2.19 (0.65–7.41)
0 (0)
0 (0)
0 (0)
1 (1.9) 0.50
11 (20.8) 0.68 1.27 (0.41–3.97)
225 (59–487) 0.01
874 (220–1,132) 0.38
53 (33–60) 0.05
25.7 (17.9–33.7) 0.12
47.0 (117–194.0) 0.79
69.0 (41.0–125.0) 0.20
28 (52.8) 0.36 0.64 (0.24–1.69)
3.7 (2.3–7.0) 0.91
2.8 (1.9–5.3) 0.75
(n 77) included. *Full recovery is defined as LVEF60% and LVEDV
F60% or LVEDV180 ml or NYHA functional classI at follow-up.ecovncom
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